Viruses, Hepatology, Cancer
Selected publications
Azoulay D, Audureau E, Bhangui P, Belghiti J, Boillot O, Andreani P, Castaing D, Cherqui D, Irtan S, Calmus Y, Chazouillères O, Soubrane O, Luciani A, Feray C. Living or Brain-dead Donor Liver Transplantation for Hepatocellular Carcinoma: A Multicenter, Western, Intent-to-treat Cohort Study.
Ann Surg. 2017 Dec;266(6):1035-1044.CE Costentin, T Decaens, A Laurent, JC Nault, B Paule, C Letoublon, Alain Luciani, Julien Calderaro, R Adam, I Bricault, Giuliana Amaddeo, D Cherqui, A Mallat, D Samuel, C Duvoux, N Ganne-Carrie, F Roudot-Thoraval, E Vibert, Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis
Liver Int. 01/12/2017;37(12) : 1869-1876 10.1111/liv.13491 13/07/2017N De'Angelis, S Abdalla, V Lizzi, F Esposito, P Genova, L Roy, F Galacteros, Alain Luciani, F Brunetti, Incidence and predictors of portal and splenic vein thrombosis after pure laparoscopic splenectomy
Surgery. 01/12/2017;162(6) : 1219-1230 10.1016/j.surg.2017.07.016 14/09/2017F Le Gal, Ségolène BRICHLER, T Drugan, C Alloui, D Roulot, Jean-Michel PAWLOTSKY, P Deny, Emmanuel GORDIEN, Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains
Hepatology. 01/12/2017;66(6) : 1826-1841 10.1002/hep.29574. 30/10/2017C Lim, H Shinkawa, K Hasegawa, P Bhangui, C Salloum, C Gomez Gavara, E Lahat, K Omichi, J Arita, Y Sakamoto, P Compagnon, Cyrille FERAY, N Kokudo, D Azoulay, Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis
Liver Transpl. 01/12/2017;23(12) : 1553-1563 10.1002/lt.24952.M Bazinet, V Pantea, V Cebotarescu, L Cojuhari, P Jimbei, JK Albrecht, P Schmid, F Le Gal, Emmanuel GORDIEN, A Krawczyk, H Mijocevic, H Karimzadeh, M Roggendorf, A Vaillant, Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
Lancet Gastroenterol hepatol. 01/12/2017;2(12) : 877-889 10.1016/S2468-1253(17)30288-1. 28/09/2017AD Marshall, EB Cunningham, S Nielsen, A Aghemo, H Alho, M Backmund, P Bruggmann, O Dalgard, C Seguin-Devaux, R Flisiak, GR Foster, L Gheorge, D Goldberg, I Goulis, M Hickman, P Hoffmann, L Janconriene, P Jarcuska, M Kaberg, LG Kostrikis, M Makara, M Maimets, RT Marinho, M Maticic, S Norris, S Olafsson, A Ovrehus, Jean-Michel PAWLOTSKY, J Pocock, G Robayes, C Roncero, M Simonova, J Sperl, M Tait, I Tolmane, S Tomaselli, M van der Valk, A Vince, GJ Dore, JV Lazarus, J Grebely, International Network on Hepatitis in Substance Users (INHSU), Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe
Lancet Gastroenterol Hepatol. 27/11/2017;pii: S2468-1253(17) : 30284-4 0.1016/S2468-1253(17)30284-4. 27/11/2017S Mule, F Pigneur, R Quelever, A Tenenhaus, L Baranes, P Richard, Vania TACHER, E Herin, H Pasquier, M Ronot, A Rahmouni, V Vilgrain, Alain LUCIANI, Can dual-energy CT replace perfusion CT for the functional evaluation of advanced hepatocellular carcinoma?
Eur Radiol. 22/11/2017;. : . 10.1007/s00330-017-5151-y.A Brown, Christophe HEZODE, E Zuckerman, GR Foster, A Zekry, SK Roberts, F Lahser, C Durkan, C Badshah, B Zhang, M Robertson, J Wahl, E Barr, B Haber, C-SCAPE Study Investigators, Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study
J Viral Hepat. 20/11/2017;. : . 10.1111/jvh.12801F Poordad, S Pol, A Asatryan, M Buti, D Shaw, Christophe HEZODE, F Felizarta, RW Reindollar, SC Gordon, S Pianko, MW Fried, D Bernstein, J Gallant, CW Lin, Y Lei, TI Ng, P Krishnan, S Kopecky-Bromberg, J Kort, FJ Mensa, Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure
Hepatology. 20/11/2017;. : . 10.1002/hep.29671
The team
- Responsable : Jean-Michel Pawlotsky
- Chercheur : Noémie Berry, Camille Boulagnon-Rombi, Daniel Candotti, Fatima Clerc, Patrick Ingiliz, Isaac Ruiz-Chavez
- Enseignant-Chercheur : Ségolène Brichler, Arthur Brouillet, Patrice Bruscella, Julien Calderaro, Stefano Caruso, Stéphane Chevaliez, Slim Fourati, Emmanuel Gordien, Fouad Lafdil, Alexis Laurent, Vincent Leroy, Alain Luciani, Sébastien Mulé, Jean-Michel Pawlotsky, Rami Rhaiem, Christophe Rodriguez, Dominique Roulot-Marullo, Daniele Sommacale, Vania Tacher
- Praticien hospitalier : Chakib Alloui, Giuliana Amaddeo, Magali Bouvier-Alias, Pierre Cappy, Dominique Challine, Hélène Regnault
- Doctorant : François Berry, Manon Delaplace, Haytham Derbel, Amel Kheyar, Denis-Salomon Lopez-Molina, Camilia Machou, Margot Morin-Dewaele, Cong-Trung Nguyen, Aurélie Rodrigues
- Ingénieur : Abdelhakim Ahmed-Belkacem, Nazim Ahnou, Rozenn Brillet, Maelenn-Pailine Delcourt, Vanessa Demontant, Frédéric Le Gal, Pascale Maillé, Mélanie Mercier-Darty, Anaïs Nguyen-Goument, Alexandre Soulier
- Technicien : Lila Poiteau
- Gestionnaire : Julia Fonseca
Address
IMRB – Inserm U955
Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18)
Building P – Entresol 1
Hôpital Henri Mondor
51, avenue du Maréchal De Lattre de Tassigny
94010 Créteil
France
Administrative assistant – Contact
Tel. : +33-1 49 81 36 56
Access map
Department news
Hepatocellular carcinoma is responsible for one third of cancer deaths worldwide, and most often develops in a context of chronic inflammation. While the immune microenvironment of tumours plays a decisive role in their evolution and is the subject of numerous studies, the role of immunity during the early stages of carcinogenesis remains little studied. In […]
Read moreThe family Bunyaviridae is a large but unfamiliar group of viruses with more than 300 members with a spherical and helical envelope. Viruses of this family can infect a wide range of hosts, from mosquitoes to marsupials and from thrips to tomatoes. Several of the Bunyaviridae cause serious disease in humans; they represent a growing […]
Read moreVRI (Vaccine Research Institute)/ INSERM/UPEC (U955, IMRB) in collaboration with several Inserm and IRD teams has just published a study in Nature Communications on 24 July showing that Ebola survivors suffer serious immune system sequelae two years after their disease. Continuing to wreak havoc in the Democratic Republic of Congo four years after the […]
Read more